6-Acetoxy-4-chloro-7-methoxyquinazoline

We are 6-Acetoxy-4-chloro-7-methoxyquinazoline CAS:230955-75-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: 6-Acetoxy-4-chloro-7-methoxyquinazoline
CAS.NO:230955-75-6
Synonyms:
6-acetyloxy-7-methoxy-4-chloroquinazoline
4-Chloro-6-acetoxy-7-methoxyquinazoline
4-Chloro-7-methoxy-6-quinazolinol 6-acetate
6-Quinazolinol,4-chloro-7-Methoxy-,6-acetate
acetic acid 4-chloro-7-methoxyquinazolin-6-yl ester
Gefitinib interMediate V
4-Chloro-7-methoxyquinazolin-6-yl acetate
acetic acid 4-chloro-7-methoxy-6-quinazolinyl ester

Molecular Formula:C11H9ClN2O3
Molecular Weight:252.65400

Physical and Chemical Properties:
Density: 1.376 g / cm3
Boiling point: 364.609ºC at 760 mmHg
Melting point: /
Flash point: 174.309ºC
Refractive index: 1.605

Specification:
Appearance:Off-white or white powder
Purity:≥98%
Individual impurity≤0.5%
Total impurities≤1.0%
Loss on drying:≤0.5%
Residue on ignition:≤0.1%
Heavy metals:≤10ppm

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:-20°C Freezer.Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Gefitinib CAS:184475-35-2

Related News: Corden Pharma group companies offer contract development and contract manufacturing for advanced pharmaceutical intermediates, APIs, and drug product formulations with more than 1,500 individuals supporting their customers with specialized technologies in all international markets.3,5-Dimethyl-4-hydroxybenzonitrile CAS:4198-90-7 In addition to APIs, a variety of pharmaceutical excipients are contained in the medicine.1,4-dibromobutano CAS:110-52-1 “With early evidence of clinical activity for our off-the-shelf, iPSC-derived NK cell programs, we are excited to lead in bringing next-generation CAR T-cell therapies to patients and plan to submit an IND for FT819 in the first half of 2020.”4-Piperidin-4-ylmorpholine “With early evidence of clinical activity for our off-the-shelf, iPSC-derived NK cell programs, we are excited to lead in bringing next-generation CAR T-cell therapies to patients and plan to submit an IND for FT819 in the first half of 2020.”Catalent’s clinical supply network includes nine cGMP-certified clinical packaging facilities across North America, Europe and Asia, and more than 50 strategically-located depots around the world, providing local and regional options for clinical storage, distribution, expiry update and relabeling services, and clinical returns management.